Early Phase 1 Huntington's Disease Trial, Recruiting NCT06634628 Sponsor: CHDI Foundation, Inc. Condition: Huntington's Disease
Back to Huntingtons Disease

Early Phase 1 Huntington's Disease Trial, Recruiting

NCT06634628
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 64 years old (male or female).
  • Your Body Mass Index (BMI) is between 19 and 35 (a measure of body weight relative to height).
  • You are able to understand and sign a consent form agreeing to take part.
  • You are able to follow the study's requirements, such as fasting before tests and having blood samples taken.
  • You are able and willing to travel to an imaging centre in Leuven, Belgium.
  • You are willing to use appropriate contraception during the study.

If you have Huntington's disease (HD) at a certain stage, you may also need to meet these additional conditions:

  • Your Huntington's gene has a specific type of change (called a CAG expansion) with a count between 40 and 50.
  • You are classified at a particular stage of HD (Stage 2 or Stage 3) based on standard HD assessments.
  • Your score on a specific HD progression measurement falls within a certain range (confirm with trial site).

If you are a healthy volunteer (no HD), you may need to meet these conditions:

  • You have no known family history of HD, OR you have been tested and confirmed to not be at genetic risk for HD.
  • You are within 5 years of age and the same biological sex as a matched HD participant in the study (except for one group where matching is not required).

Who may not be able to join:

  • You are currently in another clinical study, or finished one less than 30 days ago.
  • You have had PET imaging (a type of body scan) in the past 12 months that, combined with this study, would exceed safe radiation limits.
  • You have a medical condition or take medication that could interfere with the study, in the opinion of the study doctor.
  • You are pregnant or breastfeeding.
  • You currently take blood-thinning or anti-clotting medications, including aspirin.
  • You have a bleeding disorder.
  • You have a strong fear of needles.
  • You have metal objects in your body that are not safe for MRI scans.
  • You have metal objects in your body that are MRI-compatible but located in the head or neck area.
  • Your blood test results show something medically significant that could put you at risk or affect the study, including testing positive for Hepatitis B, Hepatitis C, HIV-1, or HIV-2, or having other abnormal safety lab results.
  • If you have HD and take antidepressants, psychiatric medications, or supplements used to treat HD — your dose must have been stable for at least 30 days before joining (confirm with trial site).
  • If you are a healthy volunteer with a family history of HD but have never been tested for the Huntington's gene change.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

Contact this trial

Phone: +32 16344280

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
CHDI Foundation, Inc.
Registry
ClinicalTrials.gov
Start date
24 February 2026
Est. completion
1 March 2028

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

The VT (volume of distribution total) of the PET radioligand will be measured with PET imaging.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov